BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34168268)

  • 41. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
    Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Circulating BRAFV600E in the diagnosis and follow-up of differentiated papillary thyroid carcinoma.
    Pupilli C; Pinzani P; Salvianti F; Fibbi B; Rossi M; Petrone L; Perigli G; De Feo ML; Vezzosi V; Pazzagli M; Orlando C; Forti G
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3359-65. PubMed ID: 23788690
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
    Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
    BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
    [TBL] [Abstract][Full Text] [Related]  

  • 44. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.
    Klempner SJ; Gershenhorn B; Tran P; Lee TK; Erlander MG; Gowen K; Schrock AB; Morosini D; Ross JS; Miller VA; Stephens PJ; Ou SH; Ali SM
    Cancer Discov; 2016 Jun; 6(6):594-600. PubMed ID: 27048246
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Significance of Plasma
    Maeda T; Konishi H; Takaki W; Takabatake K; Matsubara D; Shoda K; Arita T; Shimizu H; Komatsu S; Shiozaki A; Kuriu Y; Otsuji E
    Anticancer Res; 2021 Apr; 41(4):1761-1769. PubMed ID: 33813380
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical Significance of BRAF Non-V600E Mutations in Colorectal Cancer: A Retrospective Study of Two Institutions.
    Shimada Y; Tajima Y; Nagahashi M; Ichikawa H; Oyanagi H; Okuda S; Takabe K; Wakai T
    J Surg Res; 2018 Dec; 232():72-81. PubMed ID: 30463788
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Detection of the BRAF V600E Mutation in Colorectal Cancer by NIR Spectroscopy in Conjunction with Counter Propagation Artificial Neural Network.
    Zhang X; Yang Y; Wang Y; Fan Q
    Molecules; 2019 Jun; 24(12):. PubMed ID: 31208050
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MSI status is associated with distinct clinicopathological features in BRAF mutation colorectal cancer: A systematic review and meta-analysis.
    Wu M; Kim YS; Ryu HS; Choi SC; Kim KY; Park WC; Kim MS; Myung JY; Choi HS; Kim EJ; Lee MY
    Pathol Res Pract; 2020 Jan; 216(1):152791. PubMed ID: 31866097
    [TBL] [Abstract][Full Text] [Related]  

  • 49.
    Garcia-Carbonero N; Martinez-Useros J; Li W; Orta A; Perez N; Carames C; Hernandez T; Moreno I; Serrano G; Garcia-Foncillas J
    Cells; 2020 Jan; 9(1):. PubMed ID: 31952366
    [No Abstract]   [Full Text] [Related]  

  • 50. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.
    Chen J; Guo F; Shi X; Zhang L; Zhang A; Jin H; He Y
    BMC Cancer; 2014 Nov; 14():802. PubMed ID: 25367198
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diagnostic value of immunohistochemistry for the detection of the BRAF V600E mutation in colorectal carcinoma.
    Ioannou M; Papamichali R; Samara M; Paraskeva E; Papacharalambous C; Baxevanidou K; Koukoulis G
    J BUON; 2016; 21(3):618-25. PubMed ID: 27569082
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Impacts of microsatellite status, RAS and BRAF mutation on postoperative follow-up strategy in stage II( and III( colorectal cancer].
    Zhang J; Wang X; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Jun; 21(6):716-720. PubMed ID: 29968248
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mutation Status and Prognostic Value of KRAS and BRAF in Southeast Iranian Colorectal Cancer Patients: First Report from Southeast of Iran.
    Yari A; Samoudi A; Afzali A; Karam ZM; Karimaldini NK; Abadi MFS; Ziasistani M; Zangouey MR; Dabiri S
    J Gastrointest Cancer; 2021 Jun; 52(2):557-568. PubMed ID: 32495109
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study.
    Taniguchi H; Okamoto W; Muro K; Akagi K; Hara H; Nishina T; Kajiwara T; Denda T; Hironaka S; Kudo T; Satoh T; Yamanaka T; Abe Y; Fukushima Y; Yoshino T
    Neoplasia; 2018 Dec; 20(12):1219-1226. PubMed ID: 30412858
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 56. BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas.
    Lee D; Cho YH; Kang SY; Yoon N; Sung CO; Suh YL
    J Surg Oncol; 2015 Mar; 111(3):359-64. PubMed ID: 25346165
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.
    Cremolini C; Di Bartolomeo M; Amatu A; Antoniotti C; Moretto R; Berenato R; Perrone F; Tamborini E; Aprile G; Lonardi S; Sartore-Bianchi A; Fontanini G; Milione M; Lauricella C; Siena S; Falcone A; de Braud F; Loupakis F; Pietrantonio F
    Ann Oncol; 2015 Oct; 26(10):2092-7. PubMed ID: 26153495
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevalence of the
    Hernández-Sandoval JA; Gutiérrez-Angulo M; Magaña-Torres MT; Alvizo-Rodríguez CR; Ramírez-Plascencia HHF; Flores-López BA; Valenzuela-Pérez JA; Peregrina-Sandoval J; Moreno-Ortiz JM; Domínguez-Valentín M; Ayala-Madrigal ML
    J Investig Med; 2020 Jun; 68(5):985-991. PubMed ID: 32184228
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.
    Xing M; Alzahrani AS; Carson KA; Shong YK; Kim TY; Viola D; Elisei R; Bendlová B; Yip L; Mian C; Vianello F; Tuttle RM; Robenshtok E; Fagin JA; Puxeddu E; Fugazzola L; Czarniecka A; Jarzab B; O'Neill CJ; Sywak MS; Lam AK; Riesco-Eizaguirre G; Santisteban P; Nakayama H; Clifton-Bligh R; Tallini G; Holt EH; Sýkorová V
    J Clin Oncol; 2015 Jan; 33(1):42-50. PubMed ID: 25332244
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quantitative analysis of wild-type and V600E mutant BRAF proteins in colorectal carcinoma using immunoenrichment and targeted mass spectrometry.
    Chen H; Hsiao YC; Chiang SF; Wu CC; Lin YT; Liu H; Zhao H; Chen JS; Chang YS; Yu JS
    Anal Chim Acta; 2016 Aug; 933():144-55. PubMed ID: 27497007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.